Clinical trial
Randomized Phase II Trial of Dose Dense Docetaxel in N+ Breast Cancer
NCT00189670 · Association Européenne de Recherche en Oncologie, Other · Completed
Key facts
| NCT number | NCT00189670 |
|---|---|
| Title | Randomized Phase II Trial of Dose Dense Docetaxel in N+ Breast Cancer |
| Official title | A Phase II Randomized Trial of 6 TEC Every 3 Weeks, Versus 4 EC Followed by 4 Taxotere Every 2 Weeks, Versus 4 Taxotere Followed by 4 EC Every 2 Weeks in Node Positive Breast Cancer |
| Lead sponsor | Association Européenne de Recherche en Oncologie, Other |
| Collaborators | Aventis Pharmaceuticals Industry Amgen |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Node Positive Breast Cancer |
| Intervention type | Procedure |
| Interventions | 6 TEC q 3 weeks, 4 EC q 2 weeks followed by 4 TXT q 2 weeks, 4 TXT q 2 weeks followed by 4 EC q 2 weeks |
| First posted | Sep 19, 2005 |
| Last update posted | Sep 19, 2005 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: